person · Reporting owner

Spiegel Robert J.

Disclosed activity across 9 companies

Tapewire entity: 34255
SEC CIK: 0001492256

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Athenex, Inc.ATNX · Entity 113753	Director	April 21, 2023	April 24, 2023
Ayala Pharmaceuticals, Inc.ADXS · Entity 93434	Director	January 19, 2023	January 23, 2023
Bio Green Med Solution, Inc.CYCC · Entity 8225	Director	June 30, 2023	July 03, 2023
Ernexa Therapeutics Inc.ERNA · Entity 8278	Director	September 14, 2026	September 22, 2026
GERON CORPGERN · Entity 4989	Director	September 30, 2026	October 02, 2026
PDS Biotechnology CorpEDGE · Entity 7939	Director	March 15, 2019	March 18, 2019
RenovoRx, Inc.RNXT · Entity 6797	Director	October 01, 2026	October 03, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Athenex, Inc.

Report date April 21, 2023 · Filed April 24, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	4,592	Reported balance After 2023-04-21 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2023-04-21 · Grant · Acquired 2,300 · Balance 4,592 F1: Shares purchased from the Issuer under a Salary Deduction and Stock Purchase Agreement at the Nasdaq Official Closing Price on the date of purchase. F2: As of February 15, 2023, the issuer effected a reverse stock split of its common stock at a ratio of 1-for-20, resulting in every 20 shares owned by the reporting person to be combined into one share of common stock.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $228.00 · Expires 2030-08-05	Direct	365	Reported balance Holding disclosure · report date 2023-04-21 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance 365 F3: This option was adjusted to reflect the reverse stock split that occurred on February 15, 2023. F4: This option vests in four equal annual installments beginning on August 5, 2021.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $76.00 · Expires 2031-08-03	Direct	438	Reported balance Holding disclosure · report date 2023-04-21 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance 438 F3: This option was adjusted to reflect the reverse stock split that occurred on February 15, 2023.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.14 · Expires 2032-06-28	Direct	875	Reported balance Holding disclosure · report date 2023-04-21 · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · Balance 875 F3: This option was adjusted to reflect the reverse stock split that occurred on February 15, 2023. F5: This option vests on June 28, 2023.

Filing footnotes · ownership attribution and instrument terms

F1: Shares purchased from the Issuer under a Salary Deduction and Stock Purchase Agreement at the Nasdaq Official Closing Price on the date of purchase.

F2: As of February 15, 2023, the issuer effected a reverse stock split of its common stock at a ratio of 1-for-20, resulting in every 20 shares owned by the reporting person to be combined into one share of common stock.

F3: This option was adjusted to reflect the reverse stock split that occurred on February 15, 2023.

F4: This option vests in four equal annual installments beginning on August 5, 2021.

F5: This option vests on June 28, 2023.

Ayala Pharmaceuticals, Inc.

Report date January 19, 2023 · Filed January 23, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $27.21 · Expires 2028-03-20	Direct	3,279	Reported balance After 2023-01-19 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-01-19 · Grant · Acquired 3,279 · Balance 3,279 F2: Received in the merger of Ayala Pharmaceuticals, Inc. ("Old Ayala") into the Issuer (the "Merger") in exchange for an employee stock option to acquire 17,500 shares of the common stock of Old Ayala for $5.10 per share. F1: This option is fully vested and exercisable.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $47.17 · Expires 2030-02-12	Direct	2,342	Reported balance After 2023-01-19 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-01-19 · Grant · Acquired 2,342 · Balance 2,342 F3: Received in the Merger in exchange for an employee stock option to acquire 12,500 shares of the common stock of Old Ayala for $8.84 per share. F1: This option is fully vested and exercisable.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $55.23 · Expires 2031-06-09	Direct	1,171	Reported balance After 2023-01-19 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-01-19 · Grant · Acquired 1,171 · Balance 1,171 F4: Received in the Merger in exchange for an employee stock option to acquire 6,250 shares of the common stock of Old Ayala for $10.35 per share. F1: This option is fully vested and exercisable.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $8.70 · Expires 2032-06-12	Direct	1,171	Reported balance After 2023-01-19 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-01-19 · Grant · Acquired 1,171 · Balance 1,171 F6: Received in the Merger in exchange for an employee stock option to acquire 6,250 shares of the common stock of Old Ayala for $1.63 per share. F5: This option vests and becomes exercisable on the earlier of (i) June 13, 2023 or (ii) one day prior to the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: This option is fully vested and exercisable.

F2: Received in the merger of Ayala Pharmaceuticals, Inc. ("Old Ayala") into the Issuer (the "Merger") in exchange for an employee stock option to acquire 17,500 shares of the common stock of Old Ayala for $5.10 per share.

F3: Received in the Merger in exchange for an employee stock option to acquire 12,500 shares of the common stock of Old Ayala for $8.84 per share.

F4: Received in the Merger in exchange for an employee stock option to acquire 6,250 shares of the common stock of Old Ayala for $10.35 per share.

F5: This option vests and becomes exercisable on the earlier of (i) June 13, 2023 or (ii) one day prior to the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer through such vesting date.

F6: Received in the Merger in exchange for an employee stock option to acquire 6,250 shares of the common stock of Old Ayala for $1.63 per share.

Bio Green Med Solution, Inc.

Report date June 30, 2023 · Filed July 03, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	39,415	Reported balance After 2023-06-30 transaction · row 1 1 source row Row 1 · 2023-06-30 · Grant · Acquired 21,219 · Balance 39,415 F1: The reporting person received an award of 21,219 restricted stock units on June 30, 2023, which shall vest in full on June 30, 2024. F2: These securities were granted to Dr. Spiegel for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.59 · Expires 2033-06-30	Direct	42,438	Reported balance After 2023-06-30 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-06-30 · Grant · Acquired 42,438 · Balance 42,438 F2: These securities were granted to Dr. Spiegel for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc.

Filing footnotes · ownership attribution and instrument terms

F1: The reporting person received an award of 21,219 restricted stock units on June 30, 2023, which shall vest in full on June 30, 2024.

F2: These securities were granted to Dr. Spiegel for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc.

Ernexa Therapeutics Inc.

Report date September 14, 2026 · Filed September 22, 2026

This filing explicitly reported no securities owned.

GERON CORP

Report date September 30, 2026 · Filed October 02, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	212,161	Reported balance After 2026-09-30 transaction · row 1 1 source row Row 1 · 2026-09-30 · Grant · Acquired 6,351 · Balance 212,161 F1: Shares issued in lieu of cash compensation for quarterly board of directors' retainer and committee fees. Number of shares issued based on the closing price of the Issuer's common stock on September 30, 2026 of $1.23 per share.

Filing footnotes · ownership attribution and instrument terms

F1: Shares issued in lieu of cash compensation for quarterly board of directors' retainer and committee fees. Number of shares issued based on the closing price of the Issuer's common stock on September 30, 2026 of $1.23 per share.

PDS Biotechnology Corp

Report date March 15, 2019 · Filed March 18, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	48,661	Reported balance After 2019-03-15 transaction · row 1 1 source row Row 1 · 2019-03-15 · Exercise / conversion · Acquired 10,000 · Balance 48,661 F1: Vesting of RSUs granted to the Reporting Person on August 14, 2018.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2019-03-15 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-03-15 · Exercise / conversion · Disposed 10,000 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of Edge common stock upon the vesting of such unit. F1: Vesting of RSUs granted to the Reporting Person on August 14, 2018. F3: These restricted stock units shall become exercisable upon the achievement of certain performance or time based criteria. F4: Expiration date is not applicable as the vested restricted stock units shall be settled on the first business day following the date that such restricted stock units vest.

Filing footnotes · ownership attribution and instrument terms

F1: Vesting of RSUs granted to the Reporting Person on August 14, 2018.

F2: Each restricted stock unit represents a contingent right to receive one share of Edge common stock upon the vesting of such unit.

F3: These restricted stock units shall become exercisable upon the achievement of certain performance or time based criteria.

F4: Expiration date is not applicable as the vested restricted stock units shall be settled on the first business day following the date that such restricted stock units vest.

RenovoRx, Inc.

Report date October 01, 2026 · Filed October 03, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.55 · Expires 2036-10-01	Direct	55,924	Reported balance After 2026-10-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-10-01 · Grant · Acquired 55,924 · Balance 55,924 F1: The shares subject to the option vest in 12 equal monthly installments beginning on November 1, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option vest in 12 equal monthly installments beginning on November 1, 2026.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Old Ayala, Inc

Report date January 19, 2023 · Filed January 24, 2023

Section 16 reporting ended · disclosed 2023-01-24. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.10 · Expires 2028-03-20	Direct	Reported balance After 2023-01-19 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-01-19 · Disposition to issuer · Disposed 17,500 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated October 18, 2022, by and among Ayala Pharmaceuticals, Inc. ("Ayala"), Advaxis, Inc. ("Advaxis"), and DOE Merger Sub, Inc., a wholly owned subsidiary of Advaxis (the "Merger Agreement"). The acquisition is more fully described in Ayala's definitive proxy statement filed with the Securities and Exchange Commission on December 12, 2022. In accordance with the terms of the Merger Agreement, each share of Ayala's common stock (the "Ayala Common Stock"), was cancelled and converted into the right to receive 0.1874 shares (the "Exchange Ratio") of Advaxis common stock (the "Advaxis Common Stock"). F2: Each outstanding option to purchase Ayala Common Stock (each an "Ayala Option") was substituted and converted automatically into an option (each, an "Advaxis Replacement Option") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. The term, exercisability and other provisions of each Advaxis Replacement Option generally remains the same as the corresponding Ayala Option. F3: This option is fully vested and exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.84 · Expires 2030-02-12	Direct	Reported balance After 2023-01-19 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-01-19 · Disposition to issuer · Disposed 12,500 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated October 18, 2022, by and among Ayala Pharmaceuticals, Inc. ("Ayala"), Advaxis, Inc. ("Advaxis"), and DOE Merger Sub, Inc., a wholly owned subsidiary of Advaxis (the "Merger Agreement"). The acquisition is more fully described in Ayala's definitive proxy statement filed with the Securities and Exchange Commission on December 12, 2022. In accordance with the terms of the Merger Agreement, each share of Ayala's common stock (the "Ayala Common Stock"), was cancelled and converted into the right to receive 0.1874 shares (the "Exchange Ratio") of Advaxis common stock (the "Advaxis Common Stock"). F2: Each outstanding option to purchase Ayala Common Stock (each an "Ayala Option") was substituted and converted automatically into an option (each, an "Advaxis Replacement Option") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. The term, exercisability and other provisions of each Advaxis Replacement Option generally remains the same as the corresponding Ayala Option. F3: This option is fully vested and exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.35 · Expires 2031-06-09	Direct	Reported balance After 2023-01-19 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-01-19 · Disposition to issuer · Disposed 6,250 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated October 18, 2022, by and among Ayala Pharmaceuticals, Inc. ("Ayala"), Advaxis, Inc. ("Advaxis"), and DOE Merger Sub, Inc., a wholly owned subsidiary of Advaxis (the "Merger Agreement"). The acquisition is more fully described in Ayala's definitive proxy statement filed with the Securities and Exchange Commission on December 12, 2022. In accordance with the terms of the Merger Agreement, each share of Ayala's common stock (the "Ayala Common Stock"), was cancelled and converted into the right to receive 0.1874 shares (the "Exchange Ratio") of Advaxis common stock (the "Advaxis Common Stock"). F2: Each outstanding option to purchase Ayala Common Stock (each an "Ayala Option") was substituted and converted automatically into an option (each, an "Advaxis Replacement Option") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. The term, exercisability and other provisions of each Advaxis Replacement Option generally remains the same as the corresponding Ayala Option. F3: This option is fully vested and exercisable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.63 · Expires 2032-06-12	Direct	Reported balance After 2023-01-19 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-01-19 · Disposition to issuer · Disposed 6,250 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated October 18, 2022, by and among Ayala Pharmaceuticals, Inc. ("Ayala"), Advaxis, Inc. ("Advaxis"), and DOE Merger Sub, Inc., a wholly owned subsidiary of Advaxis (the "Merger Agreement"). The acquisition is more fully described in Ayala's definitive proxy statement filed with the Securities and Exchange Commission on December 12, 2022. In accordance with the terms of the Merger Agreement, each share of Ayala's common stock (the "Ayala Common Stock"), was cancelled and converted into the right to receive 0.1874 shares (the "Exchange Ratio") of Advaxis common stock (the "Advaxis Common Stock"). F2: Each outstanding option to purchase Ayala Common Stock (each an "Ayala Option") was substituted and converted automatically into an option (each, an "Advaxis Replacement Option") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. The term, exercisability and other provisions of each Advaxis Replacement Option generally remains the same as the corresponding Ayala Option. F4: This option vests and becomes exercisable on the earlier of (i) June 13, 2023 or (ii) one day prior to the Company's 2023 annual meeting of shareholders, subject to the Reporting Person's continued service with the Issuer through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated October 18, 2022, by and among Ayala Pharmaceuticals, Inc. ("Ayala"), Advaxis, Inc. ("Advaxis"), and DOE Merger Sub, Inc., a wholly owned subsidiary of Advaxis (the "Merger Agreement"). The acquisition is more fully described in Ayala's definitive proxy statement filed with the Securities and Exchange Commission on December 12, 2022. In accordance with the terms of the Merger Agreement, each share of Ayala's common stock (the "Ayala Common Stock"), was cancelled and converted into the right to receive 0.1874 shares (the "Exchange Ratio") of Advaxis common stock (the "Advaxis Common Stock").

F2: Each outstanding option to purchase Ayala Common Stock (each an "Ayala Option") was substituted and converted automatically into an option (each, an "Advaxis Replacement Option") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. The term, exercisability and other provisions of each Advaxis Replacement Option generally remains the same as the corresponding Ayala Option.

F3: This option is fully vested and exercisable.

F4: This option vests and becomes exercisable on the earlier of (i) June 13, 2023 or (ii) one day prior to the Company's 2023 annual meeting of shareholders, subject to the Reporting Person's continued service with the Issuer through such vesting date.

Sucampo Pharmaceuticals, Inc.

Report date February 13, 2018 · Filed February 13, 2018

Section 16 reporting ended · disclosed 2018-02-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common Stock, Class ASEC Table I · non-derivative	Direct	Reported balance After 2018-02-13 transaction · row 1 1 source row Row 1 · 2018-02-13 · Disposition to issuer · Disposed 5,130 · Balance 0 F1: This common stock was purchased for $18.00 per share share in cash, subject to any required withholding of taxes and without interest, upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to that certain Agreement and Plan of Merger by and among Mallinckrodt plc, Sun Acquisition Co. and Sucampo Pharmaceuticals, Inc. dated December 23, 2017 (the "Merger Agreement"). The common stock consisted of restricted stock units that were accelerated as a result of the Merger Agreement.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.04 · Expires 2025-01-16	Direct	Reported balance After 2018-02-13 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-02-13 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.23 · Expires 2025-05-29	Direct	Reported balance After 2018-02-13 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-02-13 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.30 · Expires 2027-06-01	Direct	Reported balance After 2018-02-13 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-02-13 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: This common stock was purchased for $18.00 per share share in cash, subject to any required withholding of taxes and without interest, upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to that certain Agreement and Plan of Merger by and among Mallinckrodt plc, Sun Acquisition Co. and Sucampo Pharmaceuticals, Inc. dated December 23, 2017 (the "Merger Agreement"). The common stock consisted of restricted stock units that were accelerated as a result of the Merger Agreement.

F2: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 01, 2026 Filed Oct 3, 2026 01:00 UTC	RenovoRx, Inc. RNXT · Entity 6797	GrantStock Options (right to buy) · Derivative	55,924	$0.00 Strike: $1.55	$0.00	Disclosure SEC source: 0001493152-26-045580 · ownership.xml · derivative · entry 1 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,924 Underlying: Common Stock · 55,924 shares Expires 2036-10-01 F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on November 1, 2026. Read SEC document
September 30, 2026 Filed Oct 2, 2026 00:30 UTC	GERON CORP GERN · Entity 4989	GrantCommon Stock	6,351	$1.23	$7,811.73	Disclosure SEC source: 0001492256-26-000009 · form4-10012026_041003.xml · nonDerivative · entry 1 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 212,161 F1 · kind: Shares issued in lieu of cash compensation for quarterly board of directors' retainer and committee fees. Number of shares issued based on the closing price of the Issuer's common stock on September 30, 2026 of $1.23 per share. F1 · price: Shares issued in lieu of cash compensation for quarterly board of directors' retainer and committee fees. Number of shares issued based on the closing price of the Issuer's common stock on September 30, 2026 of $1.23 per share. Read SEC document
June 30, 2026 Filed Jul 1, 2026 21:45 UTC	GERON CORP GERN · Entity 4989	GrantCommon Stock	6,103	$1.28	$7,811.84	Disclosure SEC source: 0001492256-26-000007 · form4-07012026_090708.xml · nonDerivative · entry 1 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 205,810 F1 · kind: Shares issued in lieu of cash compensation for quarterly board of directors' retainer and committee fees. Number of shares issued based on the closing price of the Issuer's common stock on June 30, 2026 of $1.28 per share. F1 · price: Shares issued in lieu of cash compensation for quarterly board of directors' retainer and committee fees. Number of shares issued based on the closing price of the Issuer's common stock on June 30, 2026 of $1.28 per share. Read SEC document
May 20, 2026 Filed May 26, 2026 23:45 UTC	GERON CORP GERN · Entity 4989	GrantStock Option (right to buy) · Derivative	220,000	$0.00 Strike: $1.26	$0.00	Disclosure SEC source: 0001492256-26-000006 · form4-05262026_070511.xml · derivative · entry 1 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,000 Underlying: Common Stock · 220,000 shares Expires 2036-05-19 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the Reporting Person's continuous service with the Issuer through such dates. Read SEC document
March 31, 2026 Filed Apr 1, 2026 20:30 UTC	GERON CORP GERN · Entity 4989	GrantCommon Stock	5,243	$1.49	$7,812.07	Disclosure SEC source: 0001492256-26-000004 · form4-04012026_040401.xml · nonDerivative · entry 1 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 199,707 F1 · kind: Shares issued in lieu of cash compensation for quarterly board of directors' retainer and committee fees. Number of shares issued based on the closing price of the Issuer's common stock on March 31, 2026 of $1.49 per share. F1 · price: Shares issued in lieu of cash compensation for quarterly board of directors' retainer and committee fees. Number of shares issued based on the closing price of the Issuer's common stock on March 31, 2026 of $1.49 per share. Read SEC document
December 31, 2025 Filed Jan 5, 2026 22:40 UTC	GERON CORP GERN · Entity 4989	GrantCommon Stock	5,918	$1.32	$7,811.76	Disclosure SEC source: 0001492256-26-000003 · form4-01052026_050107.xml · nonDerivative · entry 1 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 194,464 F1 · kind: Shares issued in lieu of cash compensation for quarterly board of directors' retainer and committee fees. Number of shares issued based on the closing price of the Issuer's common stock on December 31, 2025 of $1.32 per share. F1 · price: Shares issued in lieu of cash compensation for quarterly board of directors' retainer and committee fees. Number of shares issued based on the closing price of the Issuer's common stock on December 31, 2025 of $1.32 per share. Read SEC document
October 01, 2025 Filed Oct 3, 2025 00:10 UTC	RenovoRx, Inc. RNXT · Entity 6797	GrantStock Options (right to buy) · Derivative	47,640	$0.00 Strike: $1.34	$0.00	Disclosure SEC source: 0001493152-25-016756 · ownership.xml · derivative · entry 1 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,640 Underlying: Common Stock · 47,640 shares Expires 2035-10-01 F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on November 1, 2025. Read SEC document
September 30, 2025 Filed Oct 1, 2025 20:38 UTC	GERON CORP GERN · Entity 4989	GrantCommon Stock	5,702	$1.37	$7,811.74	Disclosure SEC source: 0001628280-25-043459 · wk-form4_1759351083.xml · nonDerivative · entry 1 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 188,546 F1 · kind: Shares issued in lieu of cash compensation for quarterly board of directors' retainer and committee fees. Number of shares issued based on the closing price of the Issuer's common stock on September 30, 2025 of $1.37 per share. F1 · price: Shares issued in lieu of cash compensation for quarterly board of directors' retainer and committee fees. Number of shares issued based on the closing price of the Issuer's common stock on September 30, 2025 of $1.37 per share. Read SEC document
June 30, 2025 Filed Jul 1, 2025 20:53 UTC	GERON CORP GERN · Entity 4989	GrantCommon Stock	5,540	$1.41	$7,811.40	Disclosure SEC source: 0000886744-25-000038 · wk-form4_1751403231.xml · nonDerivative · entry 1 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 182,844 F1 · kind: Shares issued in lieu of cash compensation for quarterly board of directors' retainer and committee fees. Number of shares issued based on the closing price of the Issuer's common stock on June 30, 2025 of $1.41 per share. F1 · price: Shares issued in lieu of cash compensation for quarterly board of directors' retainer and committee fees. Number of shares issued based on the closing price of the Issuer's common stock on June 30, 2025 of $1.41 per share. Read SEC document
May 21, 2025 Filed May 22, 2025 21:00 UTC	GERON CORP GERN · Entity 4989	GrantStock Option (right to buy) · Derivative	180,000	$0.00 Strike: $1.34	$0.00	Disclosure SEC source: 0000886744-25-000021 · wk-form4_1747947631.xml · derivative · entry 1 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2035-05-20 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the Reporting Person's continuous service with the Issuer through such dates. Read SEC document
March 31, 2025 Filed Apr 2, 2025 21:30 UTC	GERON CORP GERN · Entity 4989	GrantCommon Stock	4,913	$1.59	$7,811.67	Disclosure SEC source: 0000950170-25-049594 · ownership.xml · nonDerivative · entry 1 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 177,304 F1 · kind: Shares issued in lieu of cash compensation for quarterly board of directors' retainer and committee fees. Number of shares issued based on the closing price of the Issuer's common stock on March 31, 2025 of $1.59 per share. F1 · price: Shares issued in lieu of cash compensation for quarterly board of directors' retainer and committee fees. Number of shares issued based on the closing price of the Issuer's common stock on March 31, 2025 of $1.59 per share. Read SEC document
December 31, 2024 Filed Jan 2, 2025 21:05 UTC	GERON CORP GERN · Entity 4989	GrantCommon Stock	2,206	$0.00	$0.00	Disclosure SEC source: 0000950170-25-000409 · ownership.xml · nonDerivative · entry 1 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 172,391 F1 · kind: Shares issued in lieu of cash payment for quarterly Board of Directors retainer fee. Number of shares issued based on the closing price of Geron common stock on December 31, 2024 of $3.54 per share. F1 · price: Shares issued in lieu of cash payment for quarterly Board of Directors retainer fee. Number of shares issued based on the closing price of Geron common stock on December 31, 2024 of $3.54 per share. Read SEC document
December 31, 2024 Filed Apr 2, 2025 21:10 UTC Amendment	GERON CORP GERN · Entity 4989	GrantCommon Stock	2,206	$3.54	$7,809.24	Disclosure SEC source: 0000950170-25-049554 · ownership.xml · nonDerivative · entry 1 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 172,391 F1 · kind: Shares issued in lieu of cash compensation for quarterly board of directors' retainer and committee fees. Number of shares issued based on the closing price of the Issuer's common stock on December 31, 2024 of $3.54 per share. F1 · price: Shares issued in lieu of cash compensation for quarterly board of directors' retainer and committee fees. Number of shares issued based on the closing price of the Issuer's common stock on December 31, 2024 of $3.54 per share. Read SEC document
October 01, 2024 Filed Oct 2, 2024 20:30 UTC	RenovoRx, Inc. RNXT · Entity 6797	GrantStock Options (right to buy) · Derivative	25,099	$0.00 Strike: $1.02	$0.00	Disclosure SEC source: 0001493152-24-039216 · ownership.xml · derivative · entry 1 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,099 Underlying: Common Stock · 25,099 shares Expires 2034-10-01 F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on November 1, 2024. Read SEC document
September 30, 2024 Filed Oct 1, 2024 20:05 UTC	GERON CORP GERN · Entity 4989	GrantCommon Stock	1,767	$0.00	$0.00	Disclosure SEC source: 0000950170-24-110796 · ownership.xml · nonDerivative · entry 1 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,185 F1 · kind: Shares issued in lieu of cash payment for quarterly Board of Directors retainer fee. Number of shares issued based on close price of Geron common stock on September 30, 2024 of $4.54 per share. F1 · price: Shares issued in lieu of cash payment for quarterly Board of Directors retainer fee. Number of shares issued based on close price of Geron common stock on September 30, 2024 of $4.54 per share. Read SEC document
September 30, 2024 Filed Apr 2, 2025 21:05 UTC Amendment	GERON CORP GERN · Entity 4989	GrantCommon Stock	1,767	$4.54	$8,022.18	Disclosure SEC source: 0000950170-25-049544 · ownership.xml · nonDerivative · entry 1 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,185 F1 · kind: Shares issued in lieu of cash compensation for quarterly board of directors' retainer and committee fees. Number of shares issued based on the closing price of the Issuer's common stock on September 30, 2024 of $4.54 per share. F1 · price: Shares issued in lieu of cash compensation for quarterly board of directors' retainer and committee fees. Number of shares issued based on the closing price of the Issuer's common stock on September 30, 2024 of $4.54 per share. Read SEC document
June 28, 2024 Filed Jun 28, 2024 22:50 UTC	GERON CORP GERN · Entity 4989	GrantCommon Stock	1,916	$0.00	$0.00	Disclosure SEC source: 0000950170-24-079169 · ownership.xml · nonDerivative · entry 2 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,418 F2 · kind: Shares issued in lieu of cash payment for quarterly Board of Directors retainer fee. Number of shares issued based on close price of Geron Common stock on June 28, 2024 of $4.24 per share. F2 · price: Shares issued in lieu of cash payment for quarterly Board of Directors retainer fee. Number of shares issued based on close price of Geron Common stock on June 28, 2024 of $4.24 per share. Read SEC document
June 28, 2024 Filed Apr 2, 2025 21:02 UTC Amendment	GERON CORP GERN · Entity 4989	GrantCommon Stock	1,916	$4.24	$8,123.84	Disclosure SEC source: 0000950170-25-049533 · ownership.xml · nonDerivative · entry 2 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,418 F2 · kind: Shares issued in lieu of cash compensation for quarterly board of directors' retainer and committee fees. Number of shares issued based on the closing price of the Issuer's common stock on June 28, 2024 of $4.24 per share. F2 · price: Shares issued in lieu of cash compensation for quarterly board of directors' retainer and committee fees. Number of shares issued based on the closing price of the Issuer's common stock on June 28, 2024 of $4.24 per share. Read SEC document
May 09, 2024 Filed May 10, 2024 20:05 UTC	GERON CORP GERN · Entity 4989	GrantStock Option (right to buy) · Derivative	180,000	$0.00 Strike: $3.88	$0.00	Disclosure SEC source: 0000950170-24-057799 · ownership.xml · derivative · entry 1 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2034-05-08 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the Company through such dates Read SEC document
March 29, 2024 Filed Jun 28, 2024 22:50 UTC	GERON CORP GERN · Entity 4989	GrantCommon Stock	2,462	$0.00	$0.00	Disclosure SEC source: 0000950170-24-079169 · ownership.xml · nonDerivative · entry 1 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,502 F1 · kind: Shares issued in lieu of cash payment for quarterly Board of Directors retainer fee. Number of shares issued based on close price of Geron Common stock on March 29, 2024 of $3.30 per share. F1 · price: Shares issued in lieu of cash payment for quarterly Board of Directors retainer fee. Number of shares issued based on close price of Geron Common stock on March 29, 2024 of $3.30 per share. Read SEC document
March 29, 2024 Filed Apr 2, 2025 21:02 UTC Amendment	GERON CORP GERN · Entity 4989	GrantCommon Stock	2,462	$3.30	$8,124.60	Disclosure SEC source: 0000950170-25-049533 · ownership.xml · nonDerivative · entry 1 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,502 F1 · kind: Shares issued in lieu of cash compensation for quarterly board of directors' retainer and committee fees. Number of shares issued based on the closing price of the Issuer's common stock on March 28, 2024 of $3.30 per share, as March 29, 2024 was a Nasdaq market holiday. F1 · price: Shares issued in lieu of cash compensation for quarterly board of directors' retainer and committee fees. Number of shares issued based on the closing price of the Issuer's common stock on March 28, 2024 of $3.30 per share, as March 29, 2024 was a Nasdaq market holiday. Read SEC document
January 26, 2024 Filed Jan 31, 2024 00:00 UTC	RenovoRx, Inc. RNXT · Entity 6797	PurchaseWarrants · Derivative	40,983	Not disclosed Strike: $1.22	Not disclosed	Disclosure SEC source: 0001493152-24-004370 · ownership.xml · derivative · entry 2 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,983 Underlying: Common Stock · 40,983 shares Expires not disclosed F1 · price: Reporting Person purchased 40,983 shares of common stock and warrants to purchase 40,983 shares of common stock for a purchase price of $1.22 per share of common stock and associated warrant exercisable for one share of common stock in a private placement offering by the company made pursuant to Rule 506(c) of the Securities Act of 1933, as amended. The warrants are exercisable immediately, at an exercise price of $1.22 per share, subject to certain adjustments, and expire on January 30, 2029. F1 · derivative.exercise_date: Reporting Person purchased 40,983 shares of common stock and warrants to purchase 40,983 shares of common stock for a purchase price of $1.22 per share of common stock and associated warrant exercisable for one share of common stock in a private placement offering by the company made pursuant to Rule 506(c) of the Securities Act of 1933, as amended. The warrants are exercisable immediately, at an exercise price of $1.22 per share, subject to certain adjustments, and expire on January 30, 2029. F1 · derivative.expiration_date: Reporting Person purchased 40,983 shares of common stock and warrants to purchase 40,983 shares of common stock for a purchase price of $1.22 per share of common stock and associated warrant exercisable for one share of common stock in a private placement offering by the company made pursuant to Rule 506(c) of the Securities Act of 1933, as amended. The warrants are exercisable immediately, at an exercise price of $1.22 per share, subject to certain adjustments, and expire on January 30, 2029. Read SEC document
January 26, 2024 Filed Jan 31, 2024 00:00 UTC	RenovoRx, Inc. RNXT · Entity 6797	PurchaseCommon Stock	40,983	Not disclosed	Not disclosed	Disclosure SEC source: 0001493152-24-004370 · ownership.xml · nonDerivative · entry 1 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,983 F1 · price: Reporting Person purchased 40,983 shares of common stock and warrants to purchase 40,983 shares of common stock for a purchase price of $1.22 per share of common stock and associated warrant exercisable for one share of common stock in a private placement offering by the company made pursuant to Rule 506(c) of the Securities Act of 1933, as amended. The warrants are exercisable immediately, at an exercise price of $1.22 per share, subject to certain adjustments, and expire on January 30, 2029. Read SEC document
December 29, 2023 Filed Jan 4, 2024 00:04 UTC	GERON CORP GERN · Entity 4989	GrantCommon Stock	3,406	$0.00	$0.00	Disclosure SEC source: 0001209191-24-000547 · doc4.xml · nonDerivative · entry 1 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,040 F1 · kind: Shares issued in lieu of cash payment for quarterly Board of Directors retainer fee. Number of shares issued based on closing price of the Issuer's Common Stock on December 29, 2023 of $2.11 per share. F1 · price: Shares issued in lieu of cash payment for quarterly Board of Directors retainer fee. Number of shares issued based on closing price of the Issuer's Common Stock on December 29, 2023 of $2.11 per share. Read SEC document
October 01, 2023 Filed Oct 2, 2023 20:15 UTC	RenovoRx, Inc. RNXT · Entity 6797	GrantStock Options (right to buy) · Derivative	25,099	$0.00 Strike: $1.33	$0.00	Disclosure SEC source: 0001493152-23-035037 · ownership.xml · derivative · entry 1 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,099 Underlying: Common Stock · 25,099 shares Expires 2033-10-01 F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on November 1, 2023 Read SEC document
September 29, 2023 Filed Oct 2, 2023 23:31 UTC	GERON CORP GERN · Entity 4989	GrantCommon Stock	3,390	$0.00	$0.00	Disclosure SEC source: 0001062993-23-018725 · form4.xml · nonDerivative · entry 1 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,634 F1 · kind: Shares issued in lieu of cash payment for quarterly Board of Directors retainer fee. Number of shares issued based on closing price of Geron Common Stock on September 29, 2023 of $2.12 per share. F1 · price: Shares issued in lieu of cash payment for quarterly Board of Directors retainer fee. Number of shares issued based on closing price of Geron Common Stock on September 29, 2023 of $2.12 per share. Read SEC document
June 30, 2023 Filed Jul 1, 2023 01:19 UTC	GERON CORP GERN · Entity 4989	GrantCommon Stock	2,239	$0.00	$0.00	Disclosure SEC source: 0001062993-23-014271 · form4.xml · nonDerivative · entry 1 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 157,244 F1 · kind: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price of Geron Common stock on June 30, 2023 of $3.21 per share. F1 · price: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price of Geron Common stock on June 30, 2023 of $3.21 per share. Read SEC document
June 30, 2023 Filed Jul 3, 2023 20:57 UTC	Bio Green Med Solution, Inc. CYCC · Entity 8225	GrantStock Option (right to buy) · Derivative	42,438	$0.00 Strike: $0.59	$0.00	Disclosure SEC source: 0001104659-23-077658 · tm2320411-7_4seq1.xml · derivative · entry 2 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,438 Underlying: Common Stock · 42,438 shares Expires 2033-06-30 F2 · price: These securities were granted to Dr. Spiegel for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document
June 30, 2023 Filed Jul 3, 2023 20:57 UTC	Bio Green Med Solution, Inc. CYCC · Entity 8225	GrantCommon Stock	21,219	$0.00	$0.00	Disclosure SEC source: 0001104659-23-077658 · tm2320411-7_4seq1.xml · nonDerivative · entry 1 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,415 F1 · shares: The reporting person received an award of 21,219 restricted stock units on June 30, 2023, which shall vest in full on June 30, 2024. F2 · price: These securities were granted to Dr. Spiegel for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document
May 31, 2023 Filed Jun 2, 2023 23:36 UTC	GERON CORP GERN · Entity 4989	GrantStock Option (right to buy) · Derivative	125,000	$0.00 Strike: $3.27	$0.00	Disclosure SEC source: 0001062993-23-012823 · form4.xml · derivative · entry 1 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2033-05-30 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the Company through such dates. Read SEC document
April 25, 2023 Filed Apr 27, 2023 20:43 UTC	RenovoRx, Inc. RNXT · Entity 6797	GrantStock Option (right to buy) · Derivative	43,026	$0.00 Strike: $2.74	$0.00	Disclosure SEC source: 0001493152-23-013843 · ownership.xml · derivative · entry 1 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,026 Underlying: Common Stock · 43,026 shares Expires 2033-04-25 F1 · derivative.exercise_date: Shares subject to the option vest in 36 monthly installments beginning on May 25, 2023. Read SEC document
April 21, 2023 Filed Apr 24, 2023 20:45 UTC	Athenex, Inc. ATNX · Entity 113753	GrantCommon Stock	2,300	$1.31	$3,001.50	Disclosure SEC source: 0001209191-23-025408 · doc4.xml · nonDerivative · entry 1 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,592 F1 · price: Shares purchased from the Issuer under a Salary Deduction and Stock Purchase Agreement at the Nasdaq Official Closing Price on the date of purchase. F2 · balance_after: As of February 15, 2023, the issuer effected a reverse stock split of its common stock at a ratio of 1-for-20, resulting in every 20 shares owned by the reporting person to be combined into one share of common stock. Read SEC document
March 31, 2023 Filed Apr 4, 2023 00:46 UTC	GERON CORP GERN · Entity 4989	GrantCommon Stock	3,312	$0.00	$0.00	Disclosure SEC source: 0001062993-23-008378 · form4.xml · nonDerivative · entry 1 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,005 F1 · kind: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price of Geron Common stock on March 31, 2023 of $2.17 per share. F1 · price: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price of Geron Common stock on March 31, 2023 of $2.17 per share. Read SEC document
January 19, 2023 Filed Jan 23, 2023 18:16 UTC	Ayala Pharmaceuticals, Inc. ADXS · Entity 93434	GrantStock Option · Derivative	1,171	Not disclosed Strike: $8.70	Not disclosed	Disclosure SEC source: 0001493152-23-002241 · ownership.xml · derivative · entry 4 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,171 Underlying: Common Stock · 1,171 shares Expires 2032-06-12 F6 · price: Received in the Merger in exchange for an employee stock option to acquire 6,250 shares of the common stock of Old Ayala for $1.63 per share. F5 · derivative.exercise_date: This option vests and becomes exercisable on the earlier of (i) June 13, 2023 or (ii) one day prior to the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer through such vesting date. Read SEC document
January 19, 2023 Filed Jan 23, 2023 18:16 UTC	Ayala Pharmaceuticals, Inc. ADXS · Entity 93434	GrantStock Option · Derivative	1,171	Not disclosed Strike: $55.23	Not disclosed	Disclosure SEC source: 0001493152-23-002241 · ownership.xml · derivative · entry 3 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,171 Underlying: Common Stock · 1,171 shares Expires 2031-06-09 F4 · price: Received in the Merger in exchange for an employee stock option to acquire 6,250 shares of the common stock of Old Ayala for $10.35 per share. F1 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document
January 19, 2023 Filed Jan 23, 2023 18:16 UTC	Ayala Pharmaceuticals, Inc. ADXS · Entity 93434	GrantStock Option · Derivative	2,342	Not disclosed Strike: $47.17	Not disclosed	Disclosure SEC source: 0001493152-23-002241 · ownership.xml · derivative · entry 2 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,342 Underlying: Common Stock · 2,342 shares Expires 2030-02-12 F3 · price: Received in the Merger in exchange for an employee stock option to acquire 12,500 shares of the common stock of Old Ayala for $8.84 per share. F1 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document
January 19, 2023 Filed Jan 23, 2023 18:16 UTC	Ayala Pharmaceuticals, Inc. ADXS · Entity 93434	GrantStock Option · Derivative	3,279	Not disclosed Strike: $27.21	Not disclosed	Disclosure SEC source: 0001493152-23-002241 · ownership.xml · derivative · entry 1 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,279 Underlying: Common Stock · 3,279 shares Expires 2028-03-20 F2 · price: Received in the merger of Ayala Pharmaceuticals, Inc. ("Old Ayala") into the Issuer (the "Merger") in exchange for an employee stock option to acquire 17,500 shares of the common stock of Old Ayala for $5.10 per share. F1 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document
January 19, 2023 Filed Jan 24, 2023 02:00 UTC	Old Ayala, Inc AYLA · Entity 108681	Disposition to issuerStock Option (right to buy) · Derivative	6,250	Not disclosed Strike: $1.63	Not disclosed	Disclosure SEC source: 0001213900-23-004540 · ownership.xml · derivative · entry 4 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,250 shares Expires 2032-06-12 F1 · shares: This Form 4 reports securities disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated October 18, 2022, by and among Ayala Pharmaceuticals, Inc. ("Ayala"), Advaxis, Inc. ("Advaxis"), and DOE Merger Sub, Inc., a wholly owned subsidiary of Advaxis (the "Merger Agreement"). The acquisition is more fully described in Ayala's definitive proxy statement filed with the Securities and Exchange Commission on December 12, 2022. In accordance with the terms of the Merger Agreement, each share of Ayala's common stock (the "Ayala Common Stock"), was cancelled and converted into the right to receive 0.1874 shares (the "Exchange Ratio") of Advaxis common stock (the "Advaxis Common Stock"). F2 · shares: Each outstanding option to purchase Ayala Common Stock (each an "Ayala Option") was substituted and converted automatically into an option (each, an "Advaxis Replacement Option") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. The term, exercisability and other provisions of each Advaxis Replacement Option generally remains the same as the corresponding Ayala Option. F2 · price: Each outstanding option to purchase Ayala Common Stock (each an "Ayala Option") was substituted and converted automatically into an option (each, an "Advaxis Replacement Option") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. The term, exercisability and other provisions of each Advaxis Replacement Option generally remains the same as the corresponding Ayala Option. F4 · derivative.exercise_date: This option vests and becomes exercisable on the earlier of (i) June 13, 2023 or (ii) one day prior to the Company's 2023 annual meeting of shareholders, subject to the Reporting Person's continued service with the Issuer through such vesting date. Read SEC document
January 19, 2023 Filed Jan 24, 2023 02:00 UTC	Old Ayala, Inc AYLA · Entity 108681	Disposition to issuerStock Option (right to buy) · Derivative	6,250	Not disclosed Strike: $10.35	Not disclosed	Disclosure SEC source: 0001213900-23-004540 · ownership.xml · derivative · entry 3 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,250 shares Expires 2031-06-09 F1 · shares: This Form 4 reports securities disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated October 18, 2022, by and among Ayala Pharmaceuticals, Inc. ("Ayala"), Advaxis, Inc. ("Advaxis"), and DOE Merger Sub, Inc., a wholly owned subsidiary of Advaxis (the "Merger Agreement"). The acquisition is more fully described in Ayala's definitive proxy statement filed with the Securities and Exchange Commission on December 12, 2022. In accordance with the terms of the Merger Agreement, each share of Ayala's common stock (the "Ayala Common Stock"), was cancelled and converted into the right to receive 0.1874 shares (the "Exchange Ratio") of Advaxis common stock (the "Advaxis Common Stock"). F2 · shares: Each outstanding option to purchase Ayala Common Stock (each an "Ayala Option") was substituted and converted automatically into an option (each, an "Advaxis Replacement Option") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. The term, exercisability and other provisions of each Advaxis Replacement Option generally remains the same as the corresponding Ayala Option. F2 · price: Each outstanding option to purchase Ayala Common Stock (each an "Ayala Option") was substituted and converted automatically into an option (each, an "Advaxis Replacement Option") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. The term, exercisability and other provisions of each Advaxis Replacement Option generally remains the same as the corresponding Ayala Option. F3 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document
January 19, 2023 Filed Jan 24, 2023 02:00 UTC	Old Ayala, Inc AYLA · Entity 108681	Disposition to issuerStock Option (right to buy) · Derivative	12,500	Not disclosed Strike: $8.84	Not disclosed	Disclosure SEC source: 0001213900-23-004540 · ownership.xml · derivative · entry 2 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2030-02-12 F1 · shares: This Form 4 reports securities disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated October 18, 2022, by and among Ayala Pharmaceuticals, Inc. ("Ayala"), Advaxis, Inc. ("Advaxis"), and DOE Merger Sub, Inc., a wholly owned subsidiary of Advaxis (the "Merger Agreement"). The acquisition is more fully described in Ayala's definitive proxy statement filed with the Securities and Exchange Commission on December 12, 2022. In accordance with the terms of the Merger Agreement, each share of Ayala's common stock (the "Ayala Common Stock"), was cancelled and converted into the right to receive 0.1874 shares (the "Exchange Ratio") of Advaxis common stock (the "Advaxis Common Stock"). F2 · shares: Each outstanding option to purchase Ayala Common Stock (each an "Ayala Option") was substituted and converted automatically into an option (each, an "Advaxis Replacement Option") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. The term, exercisability and other provisions of each Advaxis Replacement Option generally remains the same as the corresponding Ayala Option. F2 · price: Each outstanding option to purchase Ayala Common Stock (each an "Ayala Option") was substituted and converted automatically into an option (each, an "Advaxis Replacement Option") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. The term, exercisability and other provisions of each Advaxis Replacement Option generally remains the same as the corresponding Ayala Option. F3 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document
January 19, 2023 Filed Jan 24, 2023 02:00 UTC	Old Ayala, Inc AYLA · Entity 108681	Disposition to issuerStock Option (right to buy) · Derivative	17,500	Not disclosed Strike: $5.10	Not disclosed	Disclosure SEC source: 0001213900-23-004540 · ownership.xml · derivative · entry 1 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,500 shares Expires 2028-03-20 F1 · shares: This Form 4 reports securities disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated October 18, 2022, by and among Ayala Pharmaceuticals, Inc. ("Ayala"), Advaxis, Inc. ("Advaxis"), and DOE Merger Sub, Inc., a wholly owned subsidiary of Advaxis (the "Merger Agreement"). The acquisition is more fully described in Ayala's definitive proxy statement filed with the Securities and Exchange Commission on December 12, 2022. In accordance with the terms of the Merger Agreement, each share of Ayala's common stock (the "Ayala Common Stock"), was cancelled and converted into the right to receive 0.1874 shares (the "Exchange Ratio") of Advaxis common stock (the "Advaxis Common Stock"). F2 · shares: Each outstanding option to purchase Ayala Common Stock (each an "Ayala Option") was substituted and converted automatically into an option (each, an "Advaxis Replacement Option") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. The term, exercisability and other provisions of each Advaxis Replacement Option generally remains the same as the corresponding Ayala Option. F2 · price: Each outstanding option to purchase Ayala Common Stock (each an "Ayala Option") was substituted and converted automatically into an option (each, an "Advaxis Replacement Option") to purchase the number of shares of Advaxis Common Stock equal to the product obtained by multiplying (a) the number of shares of Ayala Common Stock subject to such Ayala Option immediately prior to the effective time of the merger, by (b) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, with each such Advaxis Replacement Option to have an exercise price per share of Advaxis Common Stock equal to (x) the per share exercise price for the shares of Ayala Common Stock subject to the corresponding Ayala Option immediately prior to the effective time of the merger, divided by (y) the Exchange Ratio, rounded up to the nearest whole cent. The term, exercisability and other provisions of each Advaxis Replacement Option generally remains the same as the corresponding Ayala Option. F3 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document
January 13, 2023 Filed Jan 17, 2023 13:19 UTC	Athenex, Inc. ATNX · Entity 113753	GrantCommon Stock	16,130	$0.19	$3,000.18	Disclosure SEC source: 0001209191-23-003402 · doc4.xml · nonDerivative · entry 1 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,830 F1 · price: Shares purchased from the Issuer under a Salary Deduction and Stock Purchase Agreement at the Nasdaq Official Closing Price on the date of purchase. Read SEC document
December 30, 2022 Filed Jan 4, 2023 01:53 UTC	GERON CORP GERN · Entity 4989	GrantCommon Stock	2,970	$0.00	$0.00	Disclosure SEC source: 0001062993-23-000091 · form4.xml · nonDerivative · entry 1 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,693 F1 · kind: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price of Geron Common stock on December 30, 2022 of $2.42 per share. F1 · price: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price of Geron Common stock on December 30, 2022 of $2.42 per share. Read SEC document
October 07, 2022 Filed Oct 12, 2022 12:34 UTC	Athenex, Inc. ATNX · Entity 113753	GrantCommon Stock	12,453	$0.24	$2,999.93	Disclosure SEC source: 0001209191-22-053419 · doc4.xml · nonDerivative · entry 1 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,700 F1 · price: Shares purchased from the Issuer under a Salary Deduction and Stock Purchase Agreement at the Nasdaq Official Closing Price on the date of purchase. Read SEC document
September 30, 2022 Filed Oct 3, 2022 21:48 UTC	GERON CORP GERN · Entity 4989	GrantCommon Stock	3,071	$0.00	$0.00	Disclosure SEC source: 0001062993-22-020176 · form4.xml · nonDerivative · entry 1 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,723 F1 · kind: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on September 30, 2022 of $2.34 per share. F1 · price: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on September 30, 2022 of $2.34 per share. Read SEC document
August 03, 2022 Filed Aug 30, 2022 22:41 UTC	Athenex, Inc. ATNX · Entity 113753	Exercise / conversionRestricted Stock Units · Derivative	8,750	$0.00	$0.00	Disclosure SEC source: 0001209191-22-048054 · doc4.xml · derivative · entry 4 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These restricted stock units, which convert into common stock on a one-for one basis, vested on August 3, 2022. F1 · derivative.exercise_date: These restricted stock units, which convert into common stock on a one-for one basis, vested on August 3, 2022. F1 · derivative.expiration_date: These restricted stock units, which convert into common stock on a one-for one basis, vested on August 3, 2022. Read SEC document
August 03, 2022 Filed Aug 30, 2022 22:41 UTC	Athenex, Inc. ATNX · Entity 113753	Exercise / conversionCommon Stock	8,750	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-048054 · doc4.xml · nonDerivative · entry 1 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,247 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These restricted stock units, which convert into common stock on a one-for one basis, vested on August 3, 2022. Read SEC document
July 20, 2022 Filed Jul 21, 2022 21:05 UTC	Athenex, Inc. ATNX · Entity 113753	GrantCommon Stock	4,508	$0.67	$3,000.07	Disclosure SEC source: 0001209191-22-042879 · doc4.xml · nonDerivative · entry 1 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,497 F1 · shares: Shares purchased from the Issuer under a Salary Deduction and Stock Purchase Agreement at the Nasdaq Official Closing Price on the date of purchase. Read SEC document
June 30, 2022 Filed Jul 2, 2022 01:24 UTC	GERON CORP GERN · Entity 4989	GrantCommon Stock	4,637	$0.00	$0.00	Disclosure SEC source: 0001062993-22-015792 · form4.xml · nonDerivative · entry 1 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,652 F1 · kind: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on June 30, 2022 of $1.55 per share. F1 · price: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on June 30, 2022 of $1.55 per share. Read SEC document
June 28, 2022 Filed Jun 29, 2022 20:19 UTC	Athenex, Inc. ATNX · Entity 113753	GrantStock Option (Right to Buy) · Derivative	17,500	$0.00 Strike: $0.46	$0.00	Disclosure SEC source: 0001209191-22-039800 · doc4.xml · derivative · entry 5 Spiegel Robert J. · CIK 0001492256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2032-06-28 F5 · derivative.exercise_date: This option vests on June 28, 2023. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.